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Very early after the identification of the human immunodeficiency virus (HIV), host genet-
ics factors were anticipated to play a role in viral control and disease progression. As early
as the mid-1990s, candidate gene studies demonstrated a central role for the chemokine
co-receptor/ligand (e.g., CCR5) and human leukocyte antigen (HLA) systems. In the last
decade, the advent of genome-wide arrays opened a new era for unbiased genetic explo-
ration of the genome and brought big expectations for the identification of new unexpected
genes and pathways involved in HIV/AIDS. More than 15 genome-wide association studies
targeting various HIV-linked phenotypes have been published since 2007. Surprisingly, only
the two HIV-chemokine co-receptors and HLA loci have exhibited consistent and repro-
ducible statistically significant genetic associations. In this chapter, we will review the
findings from the genome-wide studies focusing especially on non-progressive and HIV
control phenotypes, and discuss the current perspectives.
Keywords: genome-wide association study, SNP, HIV-1, viral control, long-term non-progression, chemokine
receptors region, HLA
INTRODUCTION
Shortly after the discovery of human immunodeficiency virus
(HIV)-1 as the etiologic agent for AIDS, it became apparent
that this infection was exhibiting a considerable phenotypic
heterogeneity at different levels:
(i) Virus acquisition: some individuals, named highly exposed
HIV-seronegatives, remain uninfected even after repeated
exposure to the virus (e.g., discordant couples, persons
exposed to HIV-contaminated blood during transfusion, or
Abbreviations: Genes: CCR2, C-C chemokine receptor 2; CCR5, C-C chemokine
receptor 5; CXCR6, C-X-C chemokine receptor 6; CYP7B1, cytochrome P450, family
7, subfamily B, polypeptide 1; HCP5, HLA complex P5; HLA, human leukocyte anti-
gen; KLF3, Kruppel-like factor 3; PARD3B, PAR-3 partitioning defective 3 homolog
B; PRMT6, protein arginine methyltransferase 6; PROX1, prospero homeobox 1;
RNF39, ring finger protein 39; RXRG, retinoid X receptor gamma; SOX5, SRY-box
5; TBC1D1, TBC1 domain family member 1; TGFBRAP1, transforming growth fac-
tor beta receptor associated protein 1; ZNRD1, zinc ribbon domain containing 1.
Cohorts: ACS, Amsterdam cohort study; ALIVE, AIDS link to intravenous experi-
ence; CHAVI, center for HIV/AIDS vaccine immunology; COS, Couples Observa-
tional Study; DCG, DC gay; DoD HIV NHS, Department of Defense HIV Natural
History Study; GISHEAL, genetic and immunological study on HIV+ European and
African LTNP; GRIV, genomics of resistance to immunodeficiency virus; HGDS,
Hemophilia Growth and Development Study; LSOCA, longitudinal studies of the
ocular complications of AIDS; MACS, multicenter AIDS cohort study; MHCS,
multicenter Hemophilia cohort study; PPHHTS, Partners in Prevention HSV/HIV
Transmission Study; PRIMO, primo infection; SFCC, San Francisco city clinic.
sex workers) (Ludlam et al., 1985; Langlade-Demoyen et al.,
1994; Fowke et al., 1996).
(ii) Disease progression: some infected individuals, named long-
term non-progressors (LTNP), are able to immunologically
control the infection for a long period of time (≥8 years)
without any antiretroviral therapy by maintaining high
CD4+ T-cells levels; other individuals, named the elite con-
trollers, are able to successfully suppress the virus to very low
or even undetectable level; in contrast, rapid progressors suc-
cumb to AIDS in absence of treatment after only a few years
of infection (Pantaleo and Fauci, 1996; Saksena et al., 2007).
(iii) Response to treatment: some individuals may develop severe
side effects in response to certain antiretroviral drugs (Het-
herington et al., 2002; Mallal et al., 2002).
This phenotypic heterogeneity may be attributed to a complex
interplay between viral, environmental, and host genetic factors,
and de facto, host genes have been extensively explored since the
1990s using candidate gene association studies. The first discov-
ery involved a 32 bp deletion in CCR5 (CCR5-∆32) coding for a
truncated and non-functional protein version of the major HIV-1
entry co-receptor. Homozygous ∆32/∆32 individuals no longer
express the co-receptor on the cell surface, which affords these
fortunate individuals near complete protection from HIV-1 infec-
tion, while ∆32/+ heterozygous individuals exhibit a decreased
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cell surface protein expression and a delayed AIDS progression
(Dean et al., 1996; Liu et al., 1996; Samson et al., 1996). This crit-
ical finding has fostered the development of a new antiretroviral
class of inhibitors, which are designed to interfere with the HIV-
CCR5 interaction, and two of them are already included in current
treatment regimens (Henrich and Kuritzkes, 2013). This success-
ful story of translation to bedside reveals the power of leverage for
host genetics in the fight against the AIDS epidemic.
Additional genetic associations were identified with HIV clini-
cal course and highlighted notably the importance of the human
leukocyte antigen (HLA) alleles (e.g., B∗27, B∗35, B∗57 ), of several
immunity-related genes (e.g., KIR, IL10, IFNγ), and of host genes
encoding HIV restriction factors (e.g., CCL5, APOBEC3G, CUL5).
While HLA associations were consistently replicated across stud-
ies (Kaslow et al., 1996; Carrington et al., 1999; Hendel et al.,
1999), others are still controversial. The functional interpreta-
tion for most of these variants is yet to be discovered, but the
detailed account of each candidate gene is beyond the scope of
this article, and has been covered by previous enlightening reviews
(Fellay, 2009; An and Winkler, 2010). Overall, most of the can-
didate gene associations displayed small to modest effect sizes,
and combined all together account for a small fraction of the
phenotype variability (O’Brien and Nelson, 2004).
KEY ADVANCE: GENOME-WIDE ASSOCIATION STUDIES
In this context, the advent of a series of technological and scien-
tific progresses enabling the exploration of nearly the entire human
genome without any a priori motivated the scientific community
to pursue the discovery of host genes contributing to HIV-related
outcomes. To a large extent, genome-wide association studies
(GWAS) were a direct consequence of the achievement of Inter-
national HapMap Consortium (2003), which compiled common
human genetic variations across several continental populations.
Due to the high correlation or linkage disequilibrium (LD) exist-
ing between genetic variants or SNPs, the complexity of the entire
human genome can be recapitulated by a smaller subset of infor-
mative SNPs, called tagSNPs. Genotyping this subset of tagSNPs
offered an unbiased exploration of most of the common genetic
variation of the human genome, opening up opportunities for
novel discoveries. At the same time, accurate high throughput chip
technologies were developed to genotype cost-effectively, rapidly,
and almost effortless hundreds of thousands to millions of SNPs in
parallel (Gunderson et al., 2005), which combined with knowledge
from the HapMap project, led to a highly prolific era for genetic
interrogation of complex diseases.
Nevertheless, this global hypothesis-free approach also carries
limitations:
(1) Genome-wide association studies requires a very large num-
ber of subjects with homogeneous ethnicity and phenotype in
order to get enough power to overcome the cost of multiple
comparisons and of very stringent genome-wide significance
threshold. Power is the key in complex diseases: in contrast
to Mendelian diseases caused by a single gene, complex dis-
eases are often caused by a multitude of variants with small to
medium effect size (odds-ratio, OR). To identify these variants
while respecting the strict statistical expectations of GWAS, a
very large number of samples is thus necessary. As an illustra-
tion of this limitation, a GWAS exploring adult height in about
200,000 Europeans identified over 180 loci with OR ranging
from 1.02 to 1.3, which explain only 10% of the variance in
adult height (Lango Allen et al., 2010).
(2) The first generation of genotyping arrays only covered com-
mon variations of the human genome (with a frequency
≥5%). As a consequence, less frequent SNPs, indels, and struc-
tural variants that may be involved in the pathogenesis could
not be identified by this approach.
(3) Genotyping arrays targeting representative tagSNPs, the iden-
tification of the true causal variant is unlikely and often
requires fine mapping.
(4) Africa contains the oldest populations in the world and has
more generational time for recombination events to occur.
African populations therefore exhibit a higher genetic diver-
sity (larger number of polymorphisms) and a lower LD
level. The genome-wide capture of common variation is thus
currently less effective in African populations compared to
European or Asian populations.
The scientific community embraced GWAS as a method to
unravel the mysteries of genetics underlying complex diseases
and traits. These studies proliferated to such a degree that a
dedicated website listing all the GWAS findings was created
(http://www.genome.gov/26525384). This enthusiasm extended
to the HIV field with the publication of over 15 GWAS since the
first article in 2007. In the next sections, we will review the main
GWAS findings by emphasizing especially the differences in gene
associations among different HIV-linked phenotypes: viral load
control, AIDS progression, and HIV acquisition.
GWAS FOCUSING ON VIRAL LOAD CONTROL
The first GWAS focusing on HIV-related outcomes was published
in 2007 for the Euro-CHAVI cohort (Fellay et al., 2007). This
international consortium assessed genetic association with sta-
ble plasma RNA viral load during the asymptomatic stage of HIV
infection for 486 European HIV-infected individuals (Figure 1).
The exploration of 550,000 tagSNPs revealed only two inde-
pendent signals respecting the genome-wide significance thresh-
old (Figure 2): rs2395029 (P = 9.36× 10−12) and rs9264942
(P = 3.77× 10−9). Both polymorphisms are located in the highly
polymorphic chromosome 6 HLA region: rs2395029 is located
in the HCP5 gene and is in near complete LD with the previ-
ously known HLA-B∗5701 HIV-1 protective allele; and rs9264942
is located 35 kb upstream HLA-C. For both associations, causal
variants were sought and functional exploration was undertaken
(see below).
To increase the power of this first study, additional European
subjects were recruited from the Euro-CHAVI consortium and
from the USA-based MACS cohort (n= 2,362 including the pre-
vious 486 participants) (Fellay et al., 2009). These individuals were
genotyped on the Illumina 550K or 1 M platforms (Figure 1),
and the analysis of RNA viral load at set point confirmed the
two previous HLA signals. Numerous significant variants were
also identified in the HLA region, but after correcting the analy-
sis for rs2395029 and rs9264942 effects, only four independent
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FIGURE 1 | Summary of GWAS design focusing on viral load control. The
histogram presents the number of subjects and red circles display the number
of SNPs covered by the genotyping arrays. Two red circles are symbolized for
one cohort when individuals were genotyped using two sets of arrays.
Individual ancestry is color-coded: blue for European, orange for African, and
green for Hispanic. The pattern of each cylinder illustrates the phenotype of
interest: plain color for plasma RNA, vertical stripes for cellular DNA, solid
diamonds for HIV controllers, and diagonal stripes for HIV progressors.
SNPs remained: C6orf12 rs259919 upstream ZNRD1, rs9468692
correlated with a missense TRIM10 variant, rs9266409 down-
stream HLA-B, and the missense rs8192591 NOTCH4 SNP. In
addition, genotyping of SNPs previously associated with viral
load control in candidate gene studies confirmed the role of
the chemokine receptors variants: CCR5-∆32, CCR5-P1, and
CCR2-64I.
Plasma HIV-RNA was assessed in 605 seroconverters from the
French PRIMO cohort during the first 6 months after HIV infec-
tion, as well as cellular HIV-DNA (reflecting the HIV reservoir) in a
subset of 590 subjects (Dalmasso et al., 2008) (Figure 1). Although
no signal passed the Bonferroni threshold for genome-wide sig-
nificance, the HIV-RNA GWAS still pointed out the importance
of the HLA region and HCP5 rs2395029 for viral load control. It
also suggested a potential chromosome 4 signal for rs11725412,
located between TBC1D1 and KLF3 genes, which was supported
by an enrichment of the protective allele in a group of 45 long-
term HIV controllers (HIV-RNA<400 copies/mL after 10 years of
infection). In the GWAS focusing on cellular HIV-DNA pheno-
type, the top signal was again HCP5 rs2395029 (P = 6.72× 10−7,
not reaching genome-wide significance), thus revealing the impor-
tance of the HLA region for both HIV replication and HIV
reservoir.
Similarly to the Euro-CHAVI cohort design, 515 HIV-infected
African-Americans with stable plasma RNA viral load at set point
were recruited from the Department of Defense HIV Natural
History Study (DoD HIV NHS) and the MACS (Figure 1) (Pelak
et al., 2010). The GWAS did not reveal any genome-wide signif-
icant signal, but supplemental HLA typing revealed LD between
the top SNP, rs2523608, and HLA-B∗5703. This HLA allele was
significantly associated with viral load control (P = 5.6× 10−10),
and explained 10% of viral load variance at set point in this cohort.
Therefore, in a similar fashion to what has been observed for
individuals of European ancestry, this first GWAS in an African
ancestry group emphasized the main role played by HLA-B∗57
alleles for viral load control.
The international HIV controllers study explored the genetic
determinants of HIV-1 control by comparing HIV controllers
(cases defined by a stable plasma HIV-RNA <2,000 copies/mL
during at least 1 year without any treatment) with untreated
chronically infected individuals (controls) with different ances-
tries: 516 cases vs. 1,196 controls for Europeans, 341 cases vs. 892
controls for African-Americans, and 117 cases vs. 560 controls
for Hispanics (Figure 1) (International HIV Controllers Study
et al., 2010). The GWAS in European individuals confirmed the
two previously known HLA SNPs and revealed two additional
independent HLA SNPs: the −35 kb HLA-C rs9264942 SNP, the
HCP5 rs2395029, rs4418214 close to MICA, and the intronic
PSORS1C3 rs3131018. The GWAS in African-Americans identi-
fied four different independent HLA SNPs: the previously known
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FIGURE 2 | Summary of the GWAS results associated with AIDS
progression and/or viral load control. In this karyotype, the
statistical significance of the GWAS hits is color-coded: red for
genome-wide significant loci and blue for candidate loci that did not
reach genome-wide significance but were considered noteworthy by
the authors of the study.
HLA-B∗5703/rs2523608, rs2255221, rs2523590, and rs9262632.
The Hispanic GWAS was performed on a much smaller sample
size and no signal reached genome-wide significance. However,
the strongest signals were also located within the HLA region.
In a study focusing on HIV-1 serodiscordant heterosexual cou-
ples from East and Southern Africa (the Partners in Prevention
HSV/HIV Transmission Study, PPHHTS) and from South Africa
and Uganda (the Couples Observational Study, COS), a subset
of 403 African seropositive individuals was available for analy-
sis with stable plasma HIV-RNA at set point (Figure 1) (Lin-
gappa et al., 2011). This GWAS did not reveal any genome-wide
significant SNP.
Overall, these various GWAS identified the HLA region as the
primary driver of viral control in individuals with European or
African ancestry.
GWAS FOCUSING ON AIDS DISEASE PROGRESSION
The Euro-CHAVI GWAS described above also explored host
genetic factors associated with AIDS progression on a subset of
337 individuals from the Euro-CHAVI cohort (Figure 3) (Fel-
lay et al., 2007). The progression phenotype was defined as the
time to antiretroviral therapy initiation or to the drop of CD4+
T-cell count below 350/µL. A set of SNPs in the chromosome 6
ZNRD1/RNF39 locus approached the genome-wide significance
threshold (Figure 2). Their effect on progression and viral load set
point was demonstrated to be independent from both the HCP5
and−35 kb HLA-C SNPs.
The first genome-wide explorations of cohorts specifically
designed to concentrate on AIDS progression rather than on viral
load control were performed in the French GRIV cohort of par-
ticipants with extreme progression profiles (Figure 3) (Le Clerc
et al., 2009; Limou et al., 2009). GRIV patients were enrolled based
on plasma CD4+ T-cell count, a major AIDS progression pre-
dictor in untreated patients. The 275 GRIV LTNP, defined by a
CD4+ T-cell count above 500/µL for more than 8 years after HIV
infection in absence of antiretroviral therapy, were compared to
1,352 HIV-1 seronegative individuals. The strongest signal asso-
ciated with long-term non-progression was obtained for HCP5
rs2395029 (P = 6.79× 10−10). As illustrated by this result, host
factors controlling viral load are likely to be correlated with stable
high CD4+ T-cell count. Likewise, this explains the abundance
of HLA SNPs (46 out of the 50 top signals) in the meta-analysis
between the GRIV LTNP and the Euro-CHAVI HIV-RNA GWAS.
These results emphasize the critical role of HLA both for early viral
control and long-term non-progression. In addition, comparable
to the Euro-CHAVI study, signals approaching genome-wide sig-
nificance were identified independently from HCP5 rs2395029 for
ZNRD1/RNF39 SNPs.
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FIGURE 3 | Summary of GWAS design focusing on disease
progression. The histogram presents the number of subjects and red
circles display the number of SNPs covered by the genotyping arrays. Two
red circles are symbolized for one cohort when individuals were
genotyped using two sets of arrays. All subjects are from European
ancestry. The different phenotypes are color-coded: gold for long-term
non-progressors (LTNP), pink for medium seroconverters, green for rapid
progressors (RP), and gray for uninfected individuals. The natural history
USA study comprises seroconverters from the following cohorts: ALIVE,
DCG, HGDS, MACS, MHCS, and SFCC.
The only GWAS addressing rapid progression to date was
performed by comparing the GRIV rapid progressors, defined
by a drop of CD4+ T-cell count below 300/µL within 3 years
after the last seronegative test, with 1,352 seronegative controls
(Figure 3) (Le Clerc et al., 2009). The limited sample size for rapid
progressors (n= 85) was not powered to detect variants respect-
ing the genome-wide significance threshold. However, the use of
an alternative statistical strategy, termed the false-discovery rate
(Benjamini and Hochberg, 1995), revealed six independent loci
potentially associated with rapid progression: PRMT6 and RXRG
(chr.1), SOX5 (chr.12), TGFBRAP1 (chr.2), and two intergenic loci
(chr.8 and chr.9). These four candidate genes were biologically
relevant for HIV/AIDS pathogenesis and notably emphasized a
potential key role for the TGFβ pathway and for HIV replication
control for progression. Nonetheless, the absence of a replica-
tion cohort enriched in rapid progressors is a severe limitation
for further investigation of this unique progression phenotype.
Similarly to the first GWAS on Euro-CHAVI, the extended
Euro-CHAVI and MACS cohort study assessed the progression
phenotype for a subset of 1,071 subjects (Figure 3) (Fellay et al.,
2009). This analysis confirmed the major role of HCP5 rs2395029
and −35 kb HLA-C rs9264942 both for viral load control and
disease progression. Due to increased power, the ZNRD1/RNF39
candidate locus was for the first time significantly associated with
AIDS progression (P = 1.8× 10−8).
The HCP5 and −35 kb HLA-C associations with disease pro-
gression are mainly driven by their influence on early viral load
control: both P-values are much weaker if viral load is considered as
a covariate in the statistical analysis of the extended Euro-CHAVI
and MACS cohort (P < 10−3). On the other hand, ZNRD1/RNF39
association is largely independent of viremia, suggesting a differ-
ent mechanism of protection (Fellay et al., 2009). Similarly in the
GRIV LTNP cohort, viral load was significantly lower in LTNP
carrying the protective HCP5 rs2395029-G allele, while none of
the ZNRD1/RNF39 polymorphisms seemed to correlate with viral
load (Limou et al., 2009). In order to identify additional host
factors impacting long-term non-progression without necessarily
controlling viral load at very low level, the GRIV LTNP GWAS data
were re-analyzed after excluding the elite controllers (with a viral
load <100 copies/mL, Figure 3) (Limou et al., 2010). Individuals
from the ACS and MACS cohorts respecting this specific non-
progression phenotype were also included to increase power. The
comparison of these 276 unique LTNP with 697 HIV-uninfected
controls revealed a significant association for CXCR6 rs2234358
(P = 2.1× 10−8, Figure 2). This newly identified chromosome 3
signal was replicated in three independent European studies and
shown to be independent from the CCR2/CCR5 and HLA asso-
ciations. CXCR6 is a minor HIV co-receptor (Deng et al., 1997)
and is involved in inflammation (Landro et al., 2009) through the
trafficking of effector T-cells (Kim et al., 2001) and the activation
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of NKT cells (Germanov et al., 2008). Interestingly, hepatic NK
mice cells were shown to develop a specific adaptive immunity to
HIV-1 antigens through a mechanism requiring the expression of
CXCR6 (Paust et al., 2010).
Another GWAS was performed on a subset of subjects enriched
with extreme progression profiles from the European-American
MACS cohort: 51 rapid progressors vs. 57 medium progressors
vs. 48 LTNP (Figure 3) (Herbeck et al., 2010). This GWAS was
the first published study using the Affymetrix genotyping arrays,
which carry a different set of SNPs (especially for the HLA region)
compared to Illumina arrays. The top 25 signals were assessed
for replication in an independent cohort of 590 seroconverters.
No SNP reached genome-wide significance, but a potential signal
was suggested for three related SNPs located 36 kb upstream the
PROX1 gene, encoding for a negative regulator of IFNγ (Wang
et al., 2008).
Patients enrolled from six USA natural history cohorts (MACS,
MHCS, DCG, HGDS, SFCC, and ALIVE) were genotyped using
large coverage Affymetrix 6.0 arrays (Figure 3) (Troyer et al.,
2011). Collectively, 755 European-American seroconverters were
evaluated for association with progression to AIDS 1987. An
intronic SNP in PARD3B reached genome-wide significance
(P = 3.37× 10−9), and several other PARD3B polymorphisms
were among the top signals (Figure 2). One of these variants was
replicated by comparing rapid progressors from the GRIV and
ACS cohorts with uninfected controls (P = 0.025). PARD3B inter-
acts with members of the SMAD family, which are involved in
multiple signaling pathways and biological activities, and directly
interact with HIV-1 (Ptak et al., 2008).
The Dutch seroconverters from ACS (n= 404) were tested for
association with survival time to AIDS 1993-diagnosis or to AIDS-
related death (Figure 3) (van Manen et al., 2011). The top 10
signals were assessed for replication in the independent GRIV
cohort,and no genome-wide significant result was revealed. Poten-
tial associations were highlighted, but to date, none of them have
been replicated. The HCP5 rs2395029 SNP trended to association
with time to AIDS 1993 or to AIDS-related death, but as previously
reported, this effect was only marginal when the analysis was cor-
rected for the effect of viral load at set point (van Manen et al.,
2009).
Finally, the French-Italian GISHEAL cohort recruited 144
LTNP defined by a CD4+ T-cell count above 500/µL for more
than 7 years after HIV infection in the absence of antiretroviral
therapy (Figure 3) (Guergnon et al., 2012). The GWAS com-
paring these LTNP with the 605 seroconverters from the PRIMO
cohort confirmed the importance of the HLA region for long-term
non-progression (rs2395029, P = 1.61× 10−11).
Surprisingly, GWAS exploring host factors involved in AIDS
disease progression only focused on population of European
ancestry. These studies confirmed that the HLA region is also
strongly associated with long-term non-progression. The chro-
mosome 6 ZNRD1/RNF39 locus, the chemokine receptor region
(CCR2/CCR5 and CXCR6), and the PARD3B gene were also iden-
tified as key regulators of disease progression. Lastly, some biolog-
ically relevant candidates genes were suggested (such as PRMT6,
TGFBRAP1, or PROX1), but they still require replication in an
independent genetic study.
GWAS FOCUSING ON HIV ACQUISITION
The first GWAS exploring HIV acquisition focused on mother-
to-child transmission in Malawi (Joubert et al., 2010). In this
underpowered study, 100 HIV+ infants and 126 HIV− infants
from HIV+ mothers enrolled in the Malaria and HIV in Preg-
nancy prospective study were compared (Figure 4), but no genetic
variant reached genome-wide significance.
A second larger GWAS performed on individuals from Malawi
compared 531 HIV+ with 848 sexually active HIV− recruited by
CHAVI in sexually transmitted infection (STI) clinics (Figure 4)
(Petrovski et al., 2011). It was assumed that the latter group was
exposed to HIV-1 because of the very high prevalence of the infec-
tion among sexually active adults in Malawi. No genome-wide
significant SNP was identified.
A third study performed on individuals from Africa explored
the HIV acquisition in serodiscordant heterosexual couples (PPH-
HTS/COS study) (Lingappa et al., 2011). In this study, the risk of
exposure to HIV was carefully scored, and 496 HIV+ individuals
were compared to 302 HIV− individuals (Figure 4). Nevertheless,
this GWAS also failed to reveal any significant signal.
A first GWAS exploring HIV acquisition in individuals from
European ancestry compared 764 HIV+ individuals from the
GRIV and ACS cohorts with 1,073 HIV− individuals (Figure 4)
(Limou et al., 2012). The top signals were assessed for replication in
two independent groups of European descent (MHCS-SFCC and
LSOCA). The rs6996198-T allele (chr.8) was significantly associ-
ated with a protection from HIV-1 infection (P = 7.76× 10−8).
This protective allele was associated with a higher CYP7B1 expres-
sion,a gene located 45 kb upstream the variant. CYP7B1 is involved
in the steroid and oxysterol metabolism (Stiles et al., 2009), but also
in immune control and regulation – notably in the IgA (Bauman
et al., 2009) and proinflammatory cytokines (Dulos et al., 2005)
production, and in the induction of programed cell death (Rusinol
et al., 2004).
Recently, European hemophiliacs exposed to potentially HIV-
contaminated blood through transfusion (CHAVI014) were inves-
tigated: 765 HIV+ individuals were compared to 430 HIV− indi-
viduals who were not CCR5-∆32 homozygous (Figure 4) (Lane
et al., 2013). The extensive screening of the genetic data did not
reveal any significant association.
In summary, the GWAS focusing on HIV acquisition did not
reveal any signal in African ancestry populations, and only one
potential association with CYP7B1 was identified in a European
ancestry study.
CAUSAL VARIANT AND FUNCTIONAL EXPLORATION
Amongst the genetic variants highlighted through the GWAS
(Figure 2), several were further explored to unravel the bio-
logical mechanism underlying the association, especially for the
HLA region. The complex LD pattern in this region makes it
very difficult to discriminate the causal variant(s), in particular
in the context of a locus rich in immune-related genes that are
all candidates of interest for the control of HIV replication and
pathogenesis, and that have almost all been previously associated
with various immune-related diseases.
For example, HCP5 rs2395029 is in LD with HLA-B∗5701, a
securely identified HLA protective allele, but is also in LD with
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FIGURE 4 | Summary of GWAS design focusing on HIV acquisition.
The histogram presents the number of subjects and red circles display the
number of SNPs covered by the genotyping arrays. Individual ancestry is
color-coded: orange for African and blue for European. The pattern of each
cylinder illustrates the phenotype of interest: plain color for HIV-infected, and
horizontal stripes for HIV-uninfected.
polymorphisms from MICB, BAT1, TNF, and LTB. MICB is a lig-
and for CD8+ T-cells and NK cells, which are both key players
in the anti-HIV immune response. BAT1 is involved in splicing
and RNA export (Reed and Hurt, 2002), and is a negative regula-
tor of proinflammatory cytokines (Allcock et al., 2001). TNF is a
key proinflammatory cytokine that has been widely investigated in
HIV-1 infection (Kedzierska and Crowe, 2001). LTB is an inflam-
mation modulator involved in the development of immune cells
(Rennert et al., 1996). HCP5 itself was considered as a candidate
of interest: since it encodes a human endogenous retrovirus with
sequence homology to HIV-1 pol (Kulski and Dawkins, 1999), it
was hypothesized that it may act as an antisense RNA interfer-
ing with HIV replication. However, the two allelic forms do not
impact HIV-1 replication in vitro, suggesting that HCP5 rs2395029
is probably not the causal variant (Yoon et al., 2010). HLA-B∗5701
was previously associated with low viremia and delayed onset of
AIDS through candidate gene studies (Stephens, 2005). The poten-
tial function of this allele has been widely explored: notably, the
presentation of specific HIV-1 epitopes able to initiate a strong
cytotoxic T-lymphocyte response, and the TCR clonotype recog-
nizing the HLA-peptide complex were largely emphasized (Klein
et al., 1998; Migueles et al., 2000; Gillespie et al., 2002, 2006; Miura
et al., 2009; Elahi et al., 2011; Chen et al., 2012; Kloverpris et al.,
2012). Following this path, the international HIV controllers study
confirmed the overwhelming importance of HLA alleles for viral
control (B∗5701, B∗2705, B∗14/C∗0802, B∗52, and A∗25 as pro-
tective alleles, and B∗35 and C∗07 as risk alleles) and identified
putative causal variants in the HLA-B peptide-binding groove
(including residues at position 67, 70, and 97) in Europeans (Inter-
national HIV Controllers Study et al., 2010). Similarly in African-
Americans, they confirmed the importance of HLA-B∗5703 and
HLA-B∗8101 alleles for viral control and identified the HLA-B
groove residues 63, 97, and 116 as critical for the association (Inter-
national HIV Controllers Study et al., 2010; McLaren et al., 2012a).
Even though the mechanisms underpinning HIV-1 control and
disease non-progression remain unclear, these coding variants are
predicted to impact the conformation of the HLA-B groove and the
HIV peptides that are presented, as well as the subsequent engage-
ment of TCR or other receptors (such as the NK cell receptors).
As suggested by the recent study by McLaren et al. (2012a), the
role played by HLA-B on viral control does not rule out the impli-
cation of other polymorphisms in the HLA region, outside the
HLA-B binding groove and possibly outside the class I HLA genes.
The −35 kb (HLA-C)-C allele, associated with viral control,
was correlated with higher HLA-C gene expression (Stranger et al.,
2005) and higher HLA-C cell surface expression (Thomas et al.,
2009). The signal was proposed to be the result of LD between the
−35 kb-T allele and the HLA-C∗07 allele, known to be associated
with very low cell surface expression and more rapid disease pro-
gression (Corrah et al., 2011). Interestingly, the−35 kb-T allele was
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also demonstrated to be in LD with a polymorphism of the HLA-C
3′UTR (ins263 or rs67384697-G): this polymorphism results in the
creation of a binding site for miR-148a causing the silencing of the
HLA-C mRNA expression and a low HLA-C cell surface expression
(Figure 5) (Kulkarni et al., 2011). This mechanism offers a highly
plausible functional basis for the high HLA-C cell surface expres-
sion observed amongst HIV-infected individuals controlling the
virus replication. However, since HLA-C expression occurs as a
continuous gradient rather than a bimodal pattern that would be
expected if miR-148a were the sole regulation pathway, additional
unknown factors are likely to affect HLA-C expression.
Finally, a set of chromosome 6 SNPs in the ZNRD1/RNF39
locus was associated with AIDS progression independently from
the HCP5 rs2395029 and −35 kb HLA-C signals. ZNRD1 and
RNF39 encode for an RNA polymerase I subunit and for an
unknown ring finger protein, respectively. ZNRD1 expression was
significantly correlated to several SNPs associated with CD4+ T-
cell depletion (Stranger et al., 2005). In addition, ZNRD1 was
identified as 1 of the 273 host proteins required for HIV-1 infec-
tion and replication in a genome-wide siRNA screen (Brass et al.,
2008). An independent study confirmed that the down-regulation
of ZNRD1 through siRNA or shRNA impaired HIV-1 replica-
tion at the transcription level (Ballana et al., 2010), suggesting
strongly that ZNRD1 is the causal factor for the ZNRD1/RNF39
associations.
In addition to these three loci, all securely replicated associa-
tions revealed by GWAS (red in Figure 2) require further func-
tional studies in order to fully understand their causal relationship
with HIV control or disease pathogenesis. Potential associations
(light blue in Figure 2) require independent replication to support
further functional studies.
ALTERNATIVE EXPLORATIONS
Beyond the main GWAS results described above, we believe that
other strategies and HIV phenotypes deserve to be mentioned.
Low-frequency SNPs (<5%) are predicted to have larger effect
size and contribute to phenotype, but are often overlooked
in GWAS because of power. An interesting study re-analyzed
data from three European GWAS focusing on these neglected
low-frequency SNPs (Le Clerc et al., 2011). The comparison
of 365 LTNP with 1,394 HIV-negative controls on 8,584 low-
frequency SNPs revealed two independent associations: the HCP5
FIGURE 5 | −35 kb HLA-C functional story. This picture illustrates the
strong linkage disequilibrium between −35 kb HLA-C (rs9264942) and
the 3′UTR indel263 (rs67384697): the −35 kb-C allele is strongly
correlated with the deletion, when the −35 kb-T allele is strongly
correlated with the insertion of a G nucleotide. If the mRNA carries the
−35 kb-T/insertion haplotype, the human miR-148a can bind to the
HLA-C 3′UTR and silence its expression, leading to a low HLA-C cell
surface expression. However, if the mRNA carries the −35 kb-C/deletion
haplotype, miR-148a cannot bind efficiently to the HLA-C 3′UTR
anymore, and HLA-C cell surface expression is increased. This
mechanism would mostly explain the association between the −35 kb
HLA-C polymorphism and viral control.
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rs2395029 signal (P = 8.54× 10−15), and the RICH2 rs2072255
SNP (P = 3.30× 10−6). RICH2 is a factor contributing to the
externalization of BST-2/Tetherin (Rollason et al., 2009), which
prevents HIV-1 virion budding and release (Tokarev et al., 2009).
The RICH2 rs2072255 SNP is in full LD with a coding polymor-
phism predicted to impact splicing, which could thus alter RICH2
expression and its subsequent effect on HIV production.
Beyond HIV/AIDS primary incomes, GWAS investigating
metabolic, and age-related complications are also emerging: ather-
osclerosis (Shrestha et al., 2010), chronic liver disease (Rauch et al.,
2010), kidney disease (Kopp et al., 2008), neurocognitive disorder
(Levine et al., 2012). Understanding the genetic factors contribut-
ing to these conditions is essential since they tend to occur more
frequently and at an earlier age in HIV-infected subjects compared
to the general population.
Finally, a number of alternative strategies have been deployed
outside genetics in order to discover some of the host factors
involved in viral control, AIDS progression or HIV replication.
We can mention transcriptomic (mRNA expression) studies (Giri
et al., 2006; Rotger et al., 2010; Salgado et al., 2011; Vigneault et al.,
2011), proteomic studies (Coiras et al., 2006; Chan et al., 2007;
Molina et al., 2007; Ringrose et al., 2008), or siRNA and shRNA
screens (Brass et al., 2008; Konig et al., 2008; Zhou et al., 2008;
Yeung et al., 2009). Some of these studies will be further discussed
in Santa-Marta et al. (2013).
DISCUSSION AND FUTURE PERSPECTIVES
The GWAS focusing on viral control identified HLA as the primary
region involved in HIV control in both European and African
derived populations. Even if the genetic variants highlighted in
these two populations were different, it might suggest a similar
mechanism of control, engaging notably the antigen presentation
by the HLA-B molecule. A role for HLA-C was also unraveled in
Europeans through a mechanism involving variation of expression
level on the cell surface.
In addition to viral control (and not surprisingly), HLA is also
the major region involved in long-term non-progression. How-
ever, the role for the HCP5/HLA-B∗57 and −35 kb HLA-C SNPs
on disease progression was mainly driven by their influence on
early viral control. On the other hand, the independent ZNRD1
signal was associated with disease progression without impacting
directly viral replication.
Even if the design of each cohort varies, the contribution of
HLA variants was consistently replicated in the different studies
focusing on viral control and/or disease progression. The differ-
ences observed between the studies were mostly due to different
genotyping platforms. Indeed, Affymetrix and Illumina genotyp-
ing arrays have different human genome coverage: Affymetrix
SNPs were selected for their genotyping accuracy and their reg-
ular physical spacing across the genome, while Illumina selected
SNPs based on the LD (tagSNPs) from the HapMap populations,
focused on gene-centric variations, and enriched the coverage in
the highly polymorphic HLA region. In particular, the difference
of coverage for the HLA region explains why the cohorts that were
genotyped with the Affymetrix arrays (MACS and other natural
history USA cohorts (Herbeck et al., 2010; Troyer et al., 2011)
did not identify the HLA and ZNRD1 signals. Similarly, the early
Illumina 300K chips did not cover the −35 kb HLA-C variant,
when more dense Illumina chips (≥500 K) do. This explains why
this variant was not identify by the ACS, GRIV, and PRIMO stud-
ies using Illumina 300K. However, when this variant is genotyped
independently, the−35 kb HLA-C signal is replicated (van Manen
et al., 2009).
Of course, the use of different genotyping arrays is not the only
source of variation between the studies. As illustrated by Figures 1,
3, and 4, the cohort size varies across GWAS and this affects sta-
tistical power. This power concern might explain why the HLA
region was not significant in the Hispanic population from the
HIV controllers study (International HIV Controllers Study et al.,
2010), although we cannot exclude that HLA is not involved in
viral control in this population.
The exploration of different HIV phenotype is also a great
source of variation in the design of all these GWAS. As an example,
the examination of a progression phenotype defined according to
time to AIDS or to AIDS-related death might explain why HLA
was not identified as the primary regulator of progression in the
ACS cohort (van Manen et al., 2011), although we cannot exclude
that a lack of power, a difference of transmission route, or another
unknown factor might account for the failure to confirm HLA.
Even if it makes it more difficult to compare results among stud-
ies, the diversity of phenotype might be advantageous when con-
sidering the discovery of the full spectrum of host factors involved
in HIV/AIDS pathogenesis. Therefore, the alternative analysis of
the GRIV LTNP after excluding individuals controlling viral load
at very low levels revealed the importance of CXCR6 in long-
term non-progression (Limou et al., 2010). This association being
largely independent of viral control, it was logically not identi-
fied by the cohorts designed to specifically investigate viral control
(Euro-CHAVI, HIV controllers, etc.). Another striking example of
the asset of exploring different endpoints is the GRIV rapid pro-
gression GWAS. This underpowered analysis revealed associations
with strong effect size (OR from 2.2 to 4.2) and biologically rel-
evant candidate genes (Le Clerc et al., 2009). Rapid progressors
are often depleted from cohorts (e.g., enrollment in Euro-CHAVI
requires a stable viral load), and thus, the absence of a powerful
replication cohort is a severe limitation for further investigation
of this unique phenotype. Consequently, it might be very useful
for the community to develop new cohorts exploring rapid pro-
gressors and other innovative phenotypes in the hope of drawing
a complete picture of AIDS pathogenesis.
Genome-wide association studies exploring the HIV acquisi-
tion were mainly disappointing since no strong signal outside the
CCR5-∆32 homozygosity were identified. The lack of significant
signals associated with HIV-1 acquisition indicates that common
genetic variants with strong effect size are unlikely to play a role in
HIV-1 susceptibility in these populations. Three and two GWAS
were performed in African and European ancestry populations,
respectively. Only the GRIV/ACS European GWAS identified an
association with chromosome 8 CYP7B1 (Limou et al., 2012). The
absence of confirmation in the European CHAVI014 Hemophilia
cohort might be due to a lack of power (see Figure 4), to a differ-
ence of phenotype (GRIV/ACS used normal population controls
when CHAVI014 used highly exposed HIV-seronegatives), to a
difference of transmission route (GRIV/ACS were mostly infected
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through sexual contact when CHAVI014 were infected through
blood-transfusion), to the identification of a false positive in the
GRIV/ACS study, or to an unidentified factor.
Altogether, the HLA and chemokine receptors (CCR2/CCR5
and CXCR6) associations explain around 20% of the variance
in viral control and/or disease progression, depending on the
cohorts. In contrast, most GWAS for common diseases or traits
(e.g., type 2 diabetes, height) have identified common variants
with small to modest effect sizes explaining a small portion of the
phenotypic variance (Lango Allen et al., 2010). With ever larger
cohorts, variants with smaller effect sizes might be discovered,
but new strategies are also needed to supplement standard genetic
analyses.
First, common variants were widely tested in the context of
HIV-infected populations of European ancestry. However, we can-
not exclude that common variants with small to medium effect size
were missed and buried below the very strict statistical threshold
(type 2 errors or false negatives) – this is especially relevant in
the context of the relatively modest sample size of the HIV/AIDS
cohorts. Increasing study power by recruiting additional individ-
uals can contribute to the discovery of new variants associated
with HIV. The examination of a bigger sample size for the Euro-
CHAVI cohort was indeed successful since it revealed additional
HLA variants and confirmed the ZNRD1 signal (Fellay et al., 2009).
An alternative solution is to focus on individuals with extreme
phenotypes (such as the LTNP, rapid progressors, the highly
exposed HIV-seronegatives), who represent a powerful contrasting
tool enriched for genetic variants associated with the phenotype.
Indeed, the GRIV cohort illustrates the power of a modest size
cohort designed with very careful extreme phenotypes to identify
new candidate genes (Le Clerc et al., 2009; Limou et al., 2009,2010).
Finally, combining several studies into large meta-analyses also
increases power and can thus contribute to the discovery of new
host factors. A collaborative effort was initiated in 2009 to create
the international consortium on HIV genomics (ICHG) in order
to combine the previously published GWAS and explore further
the different phenotypes. The first phase of meta-analysis focusing
on HIV-1 acquisition by comparing 10,000 HIV-infected subjects
with 15,000 HIV-uninfected has been completed and did not iden-
tify any new signal beyond the resistance conferred by CCR5-∆32
homozygotes, suggesting again that common host genetic vari-
ation has little influence on HIV susceptibility (McLaren et al.,
2012b). The second phase of ICHG meta-analysis is on-going and
will focus on phenotypes associated with viral control and disease
progression.
African populations have also been explored during this first
wave of GWAS, but not for the analysis of disease progression
phenotypes. This oversight stems from funding and infrastruc-
ture limitations to support large prospective cohorts. In addition,
African populations exhibit a higher genetic diversity and a lower
LD level than populations outside of Africa, and therefore require
arrays with a higher density of tagSNPs to ensure a genome-wide
capture. The new generation of genotyping arrays now offers the
simultaneous genotyping of up to 5 M tagSNPs, and incorporates
the knowledge from the 1000 Genomes Project (new public cata-
log of human genetic variants with a frequency down to 1%) (1000
Genomes Project Consortium et al., 2012). Even if the coverage is
still less effective for African populations than for European and
Asian populations, the use of these new genotyping arrays might
participate in the discovery of common and less common genetic
variants associated with HIV-related outcomes in Africans.
Other HIV-infected populations with different ancestries have
been widely disregarded in the host genetics field (e.g., Asian pop-
ulations, admixed-populations such as Latinos and Hispanics).
These populations may harbor different variants from Europeans
that also influence HIV infection, replication, and pathogenesis.
Beyond the common polymorphisms (with a frequency>5%)
targeted during the first wave of GWAS, rare SNPs, indels, and
structural variants might also contribute to HIV infection and
AIDS progression. The new generation of genotyping arrays
encompasses information for lower frequency SNPs (1–5%) from
the 1000 Genomes Project. The use of this newer high density
arrays combined with the next-generation sequencing (exome or
genome) should capture rare SNPs, indels, and structural vari-
ants, and highlight new host factors associated with HIV infection
course. Since next-generation sequencing is an expensive technol-
ogy, focusing on extreme phenotypes to emphasize the genetic
differences as in the vanguard GRIV cohort (Hendel et al., 1996)
should prove a promising strategy (McLaren et al., 2011; Pelak
et al., 2011).
The next challenges are to assess the computationally challeng-
ing gene× gene and gene× environment interactions, as well as
the role of epigenetics in HIV disease. The incorporation of bio-
logical knowledge might aide in assessing these complex interplays
under reasonable assumptions. Systems biology integrates infor-
mation from multiple“omics”sources (genomics, transcriptomics,
proteomics, etc.), and could thus disclose specific host pathways
or networks contributing to the HIV-linked phenotypes.
Finally, we cannot forget that HIV course is also impacted by
viral and environmental factors that may play a larger role than
initially suspected (Wang, 2013).
CONCLUSION
The motivation for identifying genes associated with HIV/AIDS
has gained momentum as effective vaccines and curative treat-
ments have failed to materialize. The technologic breakthrough of
genotyping arrays has opened up a prolific era in human genetics.
Relatively to the discovery of hundreds of genes involved in dozen
of complex diseases, the re-discovery of HLA and chemokine
region in the HIV/AIDS field could seem quite disappointing.
However, it is important to note that GWAS revealed that HLA
is the primary region involved in viral control. In addition, two
signals were discovered (CXCR6 and PARD3B), and candidate
regions highlighted. New strategies to exploit the large amount
of genomic data generated (e.g., meta-analyses, systems biology,
etc.) and the generation of new data (e.g., new phenotypes, new
populations, next-generation sequencing, etc.) will hopefully lead
to the discovery of new host genetic associations that could lead,
following the example of CCR5-∆32, to the development of new
antiretroviral therapy or vaccine.
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